FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
Merck received FDA approval for Keytruda plus chemotherapy for some patients with advanced esophageal or gastroesophageal junction cancer.
Oncologie Announces New Data and Analyses from Clinical Programs and Name Change to OncXerna Therapeutics
In a trial combining Keytruda with Oncologie’s investigational drug that targets phosphatidylserine, the response rate was 43% among patients with a low... Read More
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
In a recent trial, Keytruda was found to be as effective as chemotherapy in previously untreated gastric cancer patients, but it caused... Read More
Biosimilar Trastuzumab Effective in Triplet Regimen for Gastric Cancer
A biosimilar version of Herceptin taken in combination with chemo and the immune-boosting drug Keytruda reduced tumor size in a clinical trial... Read More
First-Line Pembrolizumab and Trastuzumab in HER2-Positive Esophageal, Gastric, or Gastroesophageal Junction Cancer
Patients with Her2-positive gastric cancer taking a combination of the immune-boosting drug Keytruda with Herceptin had progression-free survival rate at six months... Read More
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study
In a small trial, Keytruda combined with S-1 and oxaliplatin showed encouraging efficacy in the first-line treatment of gastric cancer.
Checkpoint Inhibitor Checks in as Treatment for Advanced Gastric Cancers
Despite mixed results in clinical trials, Keytruda is producing promising survival results in some gastric cancer patients and has promise in combination... Read More
Oncologie Pairs PS Inhibitor Bavituximab with Merck’s Keytruda for Gastric Cancer
A new clinical trial pairs Oncologie’s bavituximab with Merck’s Keytruda in advanced stomach or gastroesophageal cancer.
Leap Presents Positive Clinical Results for the Combination of DKN-01 plus Keytruda® and Provides DKN-01 Program Update
Leap Therapeutics announced that a combination of its experimental drug DKN-01 and Merck’s Keytruda had a 50% overall response rate in patients... Read More
New Combination Shows Early Promise in Gastric Cancer
A combo of the immuno-oncology drug Keytruda with the VEGFR-2 inhibitor Cyramza was well tolerated by gastric cancer patients in a phase... Read More
